Emerging nanopharmaceuticals
Abstract A budding interest in nanopharmaceuticals has generated a number of advancements throughout recent years with a focus on engineering novel applications. Nanotechnology also offers the ability to detect diseases at much earlier stages, such as finding hidden or overt metastatic colonies ofte...
Gespeichert in:
| Veröffentlicht in: | Nanomedicine 2008-12, Vol.4 (4), p.273-282 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 282 |
|---|---|
| container_issue | 4 |
| container_start_page | 273 |
| container_title | Nanomedicine |
| container_volume | 4 |
| creator | Bawarski, Willie E., Pharm D Chidlowsky, Elena, Pharm D Bharali, Dhruba J., PhD Mousa, Shaker A., PhD, MBA |
| description | Abstract A budding interest in nanopharmaceuticals has generated a number of advancements throughout recent years with a focus on engineering novel applications. Nanotechnology also offers the ability to detect diseases at much earlier stages, such as finding hidden or overt metastatic colonies often seen in patients diagnosed with breast, lung, colon, prostate, and ovarian cancer. Diagnostic applications could build upon conventional procedures using nanoparticles, such as colloidal gold, iron oxide crystals, and quantum dots. Additionally, diseases may be managed by multifunctional agents encompassing both imaging and therapeutic capabilities, thus allowing simultaneous monitoring and treatment. A detailed evaluation of each formulation is essential to expand our current nanopharmaceutical repertoire. However, the safety and long-term effects of nanoformulations must not be overlooked. This review will provide a brief discussion of the major nanopharmaceutical formulations as well as the impact of nanotechnology into the future. |
| doi_str_mv | 10.1016/j.nano.2008.06.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69816083</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1549963408000841</els_id><sourcerecordid>69816083</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-346c623eefd6420f332d1e1dc6c923ffb420edc083e4d74724b64908d0e17d623</originalsourceid><addsrcrecordid>eNqFkV1LwzAUhoMobk7_gIh45V3rycfSFkSQMT9g4IV6HbrkdKb2YyatsH9vyoaCF3p1QnjeN-Q5hJxSiClQeVXGTd60MQNIY5AxANsjYzoVWZRJwfa_z1yMyJH3JQBPALJDMqKpFACJHJOzeY1uZZvVxdC1fstdnWvsO6vzyh-TgyIMPNnNCXm9m7_MHqLF0_3j7HYRaSGgi7iQWjKOWJjwLhScM0ORGi11xnhRLMMlGg0pR2ESkTCxlCKD1ADSxITkhFxue9eu_ejRd6q2XmNV5Q22vVcyS6kM8X9BmvGEwxQCyLagdq33Dgu1drbO3UZRUIM8Varhw2qQp0CqIC-Eznft_bJG8xPZ2QrA9RbAIOPTolNeW2w0GutQd8q09u_-m19xXdlmMP2OG_Rl27smaFZUeaZAPQ_rG7YHKYQWQfkXB5GTHQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19373050</pqid></control><display><type>article</type><title>Emerging nanopharmaceuticals</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Bawarski, Willie E., Pharm D ; Chidlowsky, Elena, Pharm D ; Bharali, Dhruba J., PhD ; Mousa, Shaker A., PhD, MBA</creator><creatorcontrib>Bawarski, Willie E., Pharm D ; Chidlowsky, Elena, Pharm D ; Bharali, Dhruba J., PhD ; Mousa, Shaker A., PhD, MBA</creatorcontrib><description>Abstract A budding interest in nanopharmaceuticals has generated a number of advancements throughout recent years with a focus on engineering novel applications. Nanotechnology also offers the ability to detect diseases at much earlier stages, such as finding hidden or overt metastatic colonies often seen in patients diagnosed with breast, lung, colon, prostate, and ovarian cancer. Diagnostic applications could build upon conventional procedures using nanoparticles, such as colloidal gold, iron oxide crystals, and quantum dots. Additionally, diseases may be managed by multifunctional agents encompassing both imaging and therapeutic capabilities, thus allowing simultaneous monitoring and treatment. A detailed evaluation of each formulation is essential to expand our current nanopharmaceutical repertoire. However, the safety and long-term effects of nanoformulations must not be overlooked. This review will provide a brief discussion of the major nanopharmaceutical formulations as well as the impact of nanotechnology into the future.</description><identifier>ISSN: 1549-9634</identifier><identifier>EISSN: 1549-9642</identifier><identifier>DOI: 10.1016/j.nano.2008.06.002</identifier><identifier>PMID: 18640076</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Dendrimers ; Internal Medicine ; Liposomes ; Micelles ; Nanomedicine - methods ; Nanoparticles ; Nanotechnology - methods ; Quantum Dots</subject><ispartof>Nanomedicine, 2008-12, Vol.4 (4), p.273-282</ispartof><rights>Elsevier Inc.</rights><rights>2008 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-346c623eefd6420f332d1e1dc6c923ffb420edc083e4d74724b64908d0e17d623</citedby><cites>FETCH-LOGICAL-c440t-346c623eefd6420f332d1e1dc6c923ffb420edc083e4d74724b64908d0e17d623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.nano.2008.06.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18640076$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bawarski, Willie E., Pharm D</creatorcontrib><creatorcontrib>Chidlowsky, Elena, Pharm D</creatorcontrib><creatorcontrib>Bharali, Dhruba J., PhD</creatorcontrib><creatorcontrib>Mousa, Shaker A., PhD, MBA</creatorcontrib><title>Emerging nanopharmaceuticals</title><title>Nanomedicine</title><addtitle>Nanomedicine</addtitle><description>Abstract A budding interest in nanopharmaceuticals has generated a number of advancements throughout recent years with a focus on engineering novel applications. Nanotechnology also offers the ability to detect diseases at much earlier stages, such as finding hidden or overt metastatic colonies often seen in patients diagnosed with breast, lung, colon, prostate, and ovarian cancer. Diagnostic applications could build upon conventional procedures using nanoparticles, such as colloidal gold, iron oxide crystals, and quantum dots. Additionally, diseases may be managed by multifunctional agents encompassing both imaging and therapeutic capabilities, thus allowing simultaneous monitoring and treatment. A detailed evaluation of each formulation is essential to expand our current nanopharmaceutical repertoire. However, the safety and long-term effects of nanoformulations must not be overlooked. This review will provide a brief discussion of the major nanopharmaceutical formulations as well as the impact of nanotechnology into the future.</description><subject>Dendrimers</subject><subject>Internal Medicine</subject><subject>Liposomes</subject><subject>Micelles</subject><subject>Nanomedicine - methods</subject><subject>Nanoparticles</subject><subject>Nanotechnology - methods</subject><subject>Quantum Dots</subject><issn>1549-9634</issn><issn>1549-9642</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkV1LwzAUhoMobk7_gIh45V3rycfSFkSQMT9g4IV6HbrkdKb2YyatsH9vyoaCF3p1QnjeN-Q5hJxSiClQeVXGTd60MQNIY5AxANsjYzoVWZRJwfa_z1yMyJH3JQBPALJDMqKpFACJHJOzeY1uZZvVxdC1fstdnWvsO6vzyh-TgyIMPNnNCXm9m7_MHqLF0_3j7HYRaSGgi7iQWjKOWJjwLhScM0ORGi11xnhRLMMlGg0pR2ESkTCxlCKD1ADSxITkhFxue9eu_ejRd6q2XmNV5Q22vVcyS6kM8X9BmvGEwxQCyLagdq33Dgu1drbO3UZRUIM8Varhw2qQp0CqIC-Eznft_bJG8xPZ2QrA9RbAIOPTolNeW2w0GutQd8q09u_-m19xXdlmMP2OG_Rl27smaFZUeaZAPQ_rG7YHKYQWQfkXB5GTHQ</recordid><startdate>20081201</startdate><enddate>20081201</enddate><creator>Bawarski, Willie E., Pharm D</creator><creator>Chidlowsky, Elena, Pharm D</creator><creator>Bharali, Dhruba J., PhD</creator><creator>Mousa, Shaker A., PhD, MBA</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20081201</creationdate><title>Emerging nanopharmaceuticals</title><author>Bawarski, Willie E., Pharm D ; Chidlowsky, Elena, Pharm D ; Bharali, Dhruba J., PhD ; Mousa, Shaker A., PhD, MBA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-346c623eefd6420f332d1e1dc6c923ffb420edc083e4d74724b64908d0e17d623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Dendrimers</topic><topic>Internal Medicine</topic><topic>Liposomes</topic><topic>Micelles</topic><topic>Nanomedicine - methods</topic><topic>Nanoparticles</topic><topic>Nanotechnology - methods</topic><topic>Quantum Dots</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bawarski, Willie E., Pharm D</creatorcontrib><creatorcontrib>Chidlowsky, Elena, Pharm D</creatorcontrib><creatorcontrib>Bharali, Dhruba J., PhD</creatorcontrib><creatorcontrib>Mousa, Shaker A., PhD, MBA</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nanomedicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bawarski, Willie E., Pharm D</au><au>Chidlowsky, Elena, Pharm D</au><au>Bharali, Dhruba J., PhD</au><au>Mousa, Shaker A., PhD, MBA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Emerging nanopharmaceuticals</atitle><jtitle>Nanomedicine</jtitle><addtitle>Nanomedicine</addtitle><date>2008-12-01</date><risdate>2008</risdate><volume>4</volume><issue>4</issue><spage>273</spage><epage>282</epage><pages>273-282</pages><issn>1549-9634</issn><eissn>1549-9642</eissn><abstract>Abstract A budding interest in nanopharmaceuticals has generated a number of advancements throughout recent years with a focus on engineering novel applications. Nanotechnology also offers the ability to detect diseases at much earlier stages, such as finding hidden or overt metastatic colonies often seen in patients diagnosed with breast, lung, colon, prostate, and ovarian cancer. Diagnostic applications could build upon conventional procedures using nanoparticles, such as colloidal gold, iron oxide crystals, and quantum dots. Additionally, diseases may be managed by multifunctional agents encompassing both imaging and therapeutic capabilities, thus allowing simultaneous monitoring and treatment. A detailed evaluation of each formulation is essential to expand our current nanopharmaceutical repertoire. However, the safety and long-term effects of nanoformulations must not be overlooked. This review will provide a brief discussion of the major nanopharmaceutical formulations as well as the impact of nanotechnology into the future.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>18640076</pmid><doi>10.1016/j.nano.2008.06.002</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1549-9634 |
| ispartof | Nanomedicine, 2008-12, Vol.4 (4), p.273-282 |
| issn | 1549-9634 1549-9642 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69816083 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Dendrimers Internal Medicine Liposomes Micelles Nanomedicine - methods Nanoparticles Nanotechnology - methods Quantum Dots |
| title | Emerging nanopharmaceuticals |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T02%3A46%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Emerging%20nanopharmaceuticals&rft.jtitle=Nanomedicine&rft.au=Bawarski,%20Willie%20E.,%20Pharm%20D&rft.date=2008-12-01&rft.volume=4&rft.issue=4&rft.spage=273&rft.epage=282&rft.pages=273-282&rft.issn=1549-9634&rft.eissn=1549-9642&rft_id=info:doi/10.1016/j.nano.2008.06.002&rft_dat=%3Cproquest_cross%3E69816083%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19373050&rft_id=info:pmid/18640076&rft_els_id=S1549963408000841&rfr_iscdi=true |